Population Pharmacokinetic–Based Strategies for Switching Patients with Schizophrenia Between Long-Acting Injectable Formulations of Risperidone: R064766 or RBP-7000 to TV-46000
These simulations revealed switching to TV-46000 4-6 weeks after the last dose of R064766 and 4 weeks after the last dose of RBP-7000 provided generally comparable PK exposures at first dose and steady state of TV-46000. Clinician discretion will determine which switching strategy is most appropriate in context based on factors such as patient preference, scheduling convenience, and concerns about tolerability.
Authors
- Vijay Ivaturi (ORCID: https://orcid.org/0000-0002-6433-1154)
- Ziqi Yue
- Arti Phatak (ORCID: https://orcid.org/0000-0003-3856-1754)
- A. Merenlender Wagner
- Itay Perlstein
- Mark Suett (ORCID: https://orcid.org/0000-0002-6840-1535)
- Jonathan M. Meyer (ORCID: https://orcid.org/0000-0001-7294-4834)
- Kelli R. Franzenburg
- Rajendra Singh (ORCID: https://orcid.org/0000-0003-2719-4573)
- Rolf Hansen
- Sharath Kumar (ORCID: https://orcid.org/0000-0002-4020-787X)
Institutions
- Manipal Academy of Higher Education (IN)
- Harlow College (GB)
- University of California San Diego (US)
- Teva Pharmaceuticals (Israel) (IL)
- Reckitt Benckiser (United States) (US)
- Teva Pharmaceuticals (United States) (US)
- ILC Dover (United States) (US)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-10-26
- DOI
- https://doi.org/10.1007/s40120-025-00840-9
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00